University of Washington at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

University of Washington takes part in 5 sessions at ESMO 2026 in Madrid. Its program centres on HER2-positive and HER2-low breast cancer, from early-stage to first-line metastatic treatment, and also covers urothelial cancer. It presents final results of a trial giving T-DXd before surgery, with or without anastrozole or in sequence with chemotherapy, in HER2-low, hormone receptor-positive early breast cancer.

Organization

ESMO 2026 Attendance

University of Washington

Seattle, WA

washington.edu

University & institute

Public research university in Seattle, Washington, with a school of medicine.

Abstract

Fri Oct 23
13:30–13:40

LBA23 - Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer

Proffered paper 1: Breast cancer, early and advanced stage

Breast cancer

Chair

Sat Oct 24
08:30–10:00

Proffered paper 2: Breast cancer, early and advanced stage

with Seoul National University Hospital

Breast cancer

Talk

Sun Oct 25
10:55–11:15

Endocrine therapy in patients with early stage HER2-positive breast cancer

Optimising treatment for HER2+ early breast cancer

Breast cancer

Satellite

Sun Oct 25
13:05–13:20

Paradigm Shift: The First Changes in First-Line Treatment for HER2-Positive mBC in a Decade

Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with University Hospital Erlangen, Centre Eugène Marquis

Breast cancer

Satellite

Sun Oct 25
13:20–13:35

Supporting Evidence: The Data Driving Updates to the First-Line Standard of Care for HER2-Positive mBC

Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with University Hospital Erlangen, Centre Eugène Marquis

Breast cancer

Satellite

Sun Oct 25
13:35–13:50

Patient Selection: Identifying Candidates for Novel First-Line Regimens for HER2-Positive mBC

Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with University Hospital Erlangen, Centre Eugène Marquis

Breast cancer

Satellite

Sun Oct 25
13:50–14:05

Practical Implementation: Managing Care for Patients on First-Line Regimens for HER2- Positive mBC

Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with University Hospital Erlangen, Centre Eugène Marquis

Breast cancer

Satellite

Sun Oct 25
13:50–14:05

Redefining the standard across invasive urothelial carcinoma

Astellas - Why first choice matters: Optimising treatment at the earliest opportunity for patients with advanced prostate or urothelial cancer

Genitourinary cancers

Satellite

Sun Oct 25
14:05–14:30

Questions, Take-Home Learnings, and Evaluation

Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with University Hospital Erlangen, Centre Eugène Marquis

Breast cancer

Satellite

Sun Oct 25
14:23–14:28

Audience Q&A: Advanced urothelial cancer

Astellas - Why first choice matters: Optimising treatment at the earliest opportunity for patients with advanced prostate or urothelial cancer · with Hospital Clínico San Carlos, National Center for Tumor Diseases Heidelberg

Genitourinary cancers

Instantly find 20 buyers from University of Washington

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction